RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerN/A

Registered title, quoted from ClinicalTrials.gov

5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation for Pulmonary Malignancies

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Shanghai Chest Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorShanghai Chest Hospital上海市胸科医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07830095, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Pathologically confirmed or highly suspected following preoperative multidisciplinary discussion to have either: (a) primary peripheral lung cancer, with preoperative staging investigations indicating clinical stage T1N0M0, stage IA, including newly developed primary lung cancer after previous lung cancer surgery and multiple primary lung cancers; or (b) metastatic lung tumors with the primary tumor well controlled. The target lesions must have a maximum diameter ≤3 cm, with no more than 3 lesions planned for ablation. For patients without a preoperative pathological diagnosis, malignancy must be confirmed by intraoperative biopsy and pathological assessment, and all other conditions for ablation must be met before cryoablation is performed during the same procedure.

    Inclusion criterion 2

  3. Participation in another clinical trial involving treatment within the previous 3 months or concurrent participation in another clinical trial involving treatment.

    Exclusion criterion 12

  4. Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.

    Inclusion criterion 3

  5. Pregnancy or lactation, or plans to become pregnant during the study period;

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07830095, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years.
  • Pathologically confirmed or highly suspected following preoperative multidisciplinary discussion to have either: (a) primary peripheral lung cancer, with preoperative staging investigations indicating clinical stage T1N0M0, stage IA, including newly developed primary lung cancer after previous lung cancer surgery and multiple primary lung cancers; or (b) metastatic lung tumors with the primary tumor well controlled. The target lesions must have a maximum diameter ≤3 cm, with no more than 3 lesions planned for ablation. For patients without a preoperative pathological diagnosis, malignancy must be confirmed by intraoperative biopsy and pathological assessment, and all other conditions for ablation must be met before cryoablation is performed during the same procedure.
  • Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.
  • Determined by multidisciplinary assessment to be unsuitable for or unwilling to undergo surgery and radiotherapy.
  • Considered technically feasible for robotic-assisted bronchoscopy-guided cryoablation of the target lesion(s).
  • Provided written informed consent after being fully informed of the study procedures, potential benefits, and risks.

Exclusion Criteria:

  • Unable to tolerate or unwilling to undergo general anesthesia.
  • Contraindications to bronchoscopy or unwillingness to undergo bronchoscopy.
  • Receipt of any form of local tumor therapy to the target lesion(s) within 6 months before the procedure.
  • Evidence of intrathoracic lymph node metastases or extrathoracic metastases within 1 month before the procedure, except for extrathoracic metastases that had been effectively controlled by local treatment.
  • Severe bleeding tendency or uncorrectable coagulation abnormalities, including a platelet count <50 × 10\^9/L, prothrombin time >18 s, or prothrombin activity <40%.
  • Anticoagulant or antiplatelet therapy not discontinued for the required duration before the procedure.
  • Severe hepatic or renal dysfunction considered by the investigator to preclude participation in the study.
  • Uncontrolled infectious disease.
  • Severe concomitant pulmonary disease, including severe interstitial pneumonia, pulmonary fibrosis, pulmonary fibrosis with emphysema, atelectasis, or pulmonary hypertension, considered by the investigator to preclude participation in the study.
  • Acute cardiovascular or cerebrovascular events, such as acute ischemic stroke or acute coronary syndrome, within 3 months before enrollment.
  • A history of severe cardiac dysfunction and/or severe cardiac arrhythmia.
  • Participation in another clinical trial involving treatment within the previous 3 months or concurrent participation in another clinical trial involving treatment.
  • Pregnancy or lactation, or plans to become pregnant during the study period;
  • Any other condition considered by the investigator to make the patient unsuitable for enrollment.

Quoted from ClinicalTrials.gov, NCT07830095, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07830095, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07830095